Development of curative therapies for ewing sarcomas by interdisciplinary cooperative groups in Europe

T. Bölling, G. Braun-Munzinger, S. Burdach, G. Calaminus, A. Craft, O. Delattre, M. C.L. Deley, U. Dirksen, B. Dockhorn-Dworniczak, J. Dunst, S. Engel, A. Faldum, B. Fröhlich, H. Gadner, U. Göbel, G. Gosheger, J. Hardes, D. S. Hawkins, L. Hjorth, C. HoffmannH. Kovar, J. Kruseova, R. Ladenstein, I. Leuschner, I. J. Lewis, O. Oberlin, M. Paulussen, J. Potratz, A. Ranft, C. Rössig*, C. Rübe, R. Sauer, O. Schober, A. Schuck, B. Timmermann, F. Tirode, H. Van Den Berg, F. Van Valen, V. Vieth, N. Willich, W. Winkelmann, J. Whelan, R. B. Womer

*Corresponding author for this work
3 Citations (Scopus)


Curative therapies for Ewing sarcoma have been developed within cooperative groups. Consecutive clinical trials have systematically assessed the impact and timing of local therapy and the activity of cytotoxic drugs and their combinations. They have led to an increase of long-term disease-free survival to around 70% in patients with localized disease. Translational research in ES remains an area in which interdisciplinary and international cooperation is essential for future progress. This article reviews current state-of-the art therapy, with a focus on trials performed in Europe, and summarizes novel strategies to further advance both the cure rates and quality of survival.

Original languageEnglish
JournalKlinische Padiatrie
Issue number3
Pages (from-to)108-115
Number of pages8
Publication statusPublished - 22.05.2015


Dive into the research topics of 'Development of curative therapies for ewing sarcomas by interdisciplinary cooperative groups in Europe'. Together they form a unique fingerprint.

Cite this